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Abstract for Critical Review of the Literature
Background: Every woman will experience menopause, however each woman’s experience is
individual and has varying degrees of symptoms. As a woman ages estrogen production declines
and eventually ceases. Hormone replacement therapy has been used for menopausal symptom
management and for other conditions associated with declining estrogen. Information regarding
hormone replacement therapy is conflicting and confusing. Evidence exists regarding safety and
efficacy of hormone replacement therapy.
Purpose: The purpose of this critical review of the literature is to answer the practice questions
of: What are the current best practices around hormone therapy use for menopausal and
postmenopausal women? What is the current evidence regarding safety and efficacy of hormone
therapy? The Theory of Symptom Self-Management provides the framework to partner with
women to empower them to set individual health goals, to be able to make informed choices
regarding the use of hormone replacement therapy, and self-manage their symptoms safely and
effectively.
Results: Twenty-three articles were identified and evaluated for hormone replacement therapy
evidence. The evidence is confusing and can be conflicting due to the many forms of hormone
therapy, timing of treatment, length of treatment, and the misleading and unsupported
endorsements. Hormone therapy can be used for treatment of menopausal symptoms for women
as they transition into menopause. Hormone therapy has been shown to reduce cortical bone loss.
However, in any case or any form, hormone therapy should be prescribed at the lowest dose for
the shortest duration period possible. Use of hormone therapy increases a woman’s risk for
cardiovascular disease, thrombolytic events, cognitive decline, and breast cancer.
Conclusion: The review of the literature supports the evidence that hormone therapy can be used
for short duration to treat symptoms of menopause. Every woman seeking information regarding
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menopause and hormone replacement therapy should have a discussion with their provider care
team to become informed about risk versus benefit of use and alternatives. Long term patient
safety and a healthy life style should be emphasized.
Implications for Research and Practice: Providers and nurses need to be well informed about
the different forms of hormone therapy and evidence surrounding the practice. Women’s voices
need to be heard and their symptoms affirmed. The Theory of Symptom Self-Management can
be the framework for providers and nurses to partner with their patients and empower them to set
healthy goals to safely manage their symptoms.
Keywords: Menopause, post-menopausal, hormone therapy, bioidentical hormone therapy,
compounded bioidentical hormone therapy
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Chapter One: Introduction
The human body is an amazing and ever-changing dynamic system. As a woman ages,
the body goes through life changes that seem to happen quietly over time. Hormones in the body
are significant regulators during these changes. Declining estrogen and progesterone during
menopause can create unpleasant and even life-altering symptoms and contribute to other disease
formation. According to Stephenson, Neuenschwander, and Kurdowska (2013), “menopause
impacts 25 million women worldwide each year, and by 2030 the World Health Organization
estimates 1.2 billion women will be postmenopausal” (p. 74). “Menopause has been associated
with symptoms of hot flashes, night sweats, dysphoric mood, sleep disturbance, and conditions
of cardiovascular disease, depression, osteoporosis, osteoarthritis, dementia, and frailty” (p. 74).
The World Health Organization (2017) reported that one in three postmenopausal women are
impaired by osteoporosis, including a 40% lifetime risk of fractures from this devastating
disease. Also associated with menopause is an increased risk of cardiovascular disease, affecting
approximately one out of every three adult women. This increased risk of cardiovascular disease
is predominately seen in women approximately ten years after menopause (American Heart
Association, 2019). The increased risk of coronary heart disease can be partly explained by the
phenomenon of the changing lipoprotein as estrogen declines (Formby & Schmidt, 2011).
Statement of Purpose
Replacement hormone therapy, that of estrogen alone or combined with progestin, has
been used for years to help relieve menopausal symptoms (Ruiz & Daniels, 2014). Throughout
this time, there has been conflicting advice regarding hormone use. The Women's Health
Initiative study, which was initially started in 1993, released evidence in 2002 that suggested
hormone replacement therapy increased a woman's risk of stroke and breast cancer (Fishman,
Flatt, & Settersten, 2015; WHI, n.d.). Since then, other studies have been completed to assess the
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effects of hormone use with women who have pursued traditional or other alternative hormone
therapies. It is known that women are continuing to choose hormone therapy due to their
experience with devastating symptoms during the menopause transition. In 2005, it was
estimated that as many as two million women in the United States used compounded bioidentical
hormones; in the year 2007, a court ordered hearing was done by the United States Senate to
address the increase in compounded bioidentical use (Iftikhar, Shuster, Johnson, Jenkins, &
Wahner-Roedler, 2011).
Over the last several years, knowledge about hormone replacement therapy has evolved.
The practice questions to guide this critical review of the literature are: What are the current best
practices around hormone therapy for menopausal and postmenopausal women? What is the
current evidence regarding safety and efficacy of hormone therapy?
Hormone Therapy
There are several forms and types of hormone therapy available on the market today.
Most traditional hormone therapy comes in a pill form and contains conjugated equine estrogen
(Bhavnani & Stanczyk, 2012). Traditional hormone therapy is regulated and approved by the
Food and Drug Administration. Alternative forms of hormone therapy which have been
chemically modified from either plant or animal material are known as bioidentical (Fishman, et
al., 2015). There are some forms of bioidentical hormone therapy that are regulated and
approved by the Food and Drug Administration, for instance, estradiol and micronized
progesterone (L’Hermite, 2017). There are also compounded forms of bioidentical hormones.
Compounded forms are made by compounding pharmacies; these forms of hormones are not
regulated or approved by the Food and Drug Administration.
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Definitions
Identified topic-specific words and their definitions used throughout this literature review
include the following:
Menopause: the transition or biological process when the ovaries decrease production of
estrogen, which leads to the irreversible termination of menses (Schoor, 2015).
Postmenopause: a natural or surgical menopause where there has been at least one year
since menstruation (Nii et al., 2015).
Osteoporosis: an overall bone disease; bone cells do not absorb within the bone structure
which creates low bone density and leads to bone fragility and fractures. (Stephenson et al.,
2013; Ran, Yu, Chen & Lin, 2017).
Dysphoric Moods: a state of mind such as depression, anxiety, and reduced self-esteem
(Stephenson et al., 2013).
Transdermal: relating to administering medication topically, usually in the form of a
dermal patch, gel, emulsion, or spray (Archer, Pickar, MacAllister, & Warren, 2012).
Bioidentical: a chemical composition that is the same as a human composition (Sood et
al., 2013). Substances are usually extracted from plant sources and then chemically altered
(Fishman et al., 2015).
Compounded Hormone Therapy: bioidentical hormone combinations that are prepared
by a compounding pharmacist into buccal, sublingual, oral, transdermal, vaginal suppository, or
subdermal pellet forms. A prescribed individualized combination of hormones (Fishman et al.,
2015).
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History of Hormone Replacement Therapy
Hormones were discovered in the early 20th century. During this time rejuvenation
experiments and treatments were performed, using secretions extracted from testes and ovaries
and then injected into men and women (Fishman et al., 2015). In the 1930s and 40s, the
pharmaceutical companies promoted estrogen therapy to women. Over the next several decades,
hormone therapy use grew. However, many studies emerged showing an increase in cancers
associated with the use of estrogen replacement therapy. Due to this new evidence, the medical
community recommended a limit to the time frame a woman would use replacement hormone
therapy. Then in 1984, a professional medical organization invalidated any adverse claims by
promoting hormone replacement therapy for osteoporosis (Fishman et al., 2015). The next
several years brought acceptance to hormone therapy. In 1999 more than 85 million prescriptions
for hormone replacement therapy were written (Fishman et al., 2015). Yet, as mentioned earlier,
in 2002, a large scale study called the Women's Health Initiative (WHI) ended three years early
due to the adverse outcomes and findings of increased risks of heart disease, stroke, and breast
cancer (Fishman et al., 2015). Since then, there have been other observational studies performed
using subsets of the initial participants from the original study. Some of the subset observational
studies have suggested that hormone therapy provides coronary artery disease protection if
initiated close to menopause (Mikkola, Savolainen-Peltonen, Venetkoski & Ylikorkala, 2017).
Other studies demonstrate that age, pre-existing heart disease, time that the hormone therapy is
started, and routes of hormone therapy were not taken into account in the WHI study, which can
create differing outcomes (Nii et al., 2015).
Conflicting information exists regarding the risks and benefits of hormone therapy and
thus has pushed many clinicians and patients to search for an alternative to the traditional
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hormone therapy. Compounded bioidentical hormone replacement therapy is an alternative to the
commercially available Food and Drug Administration approved bioidentical products. Bhavnani
and Stanczyk (2012) suggest that, due to the conflicting information and distrust with traditional
medicine, compounded hormones have become more popular.
Evidence Suggesting Need for Critical Review
A large study around the health effects of oral hormone replacement was stopped by the
World Health Organization in 2002 because the health risks were determined to outweigh the
health benefits for the women involved (World Health Organization, 2017). The study started
enrollment in 1993 and was part of an attempt to raise awareness around health and focus on
prevention of chronic diseases in postmenopausal women (National Heart, Lung, and Blood
Institute, 2010; WHI, n.d.). The Women's Health Initiative involved 161,808 women aged 50-79
(National Heart, Lung, and Blood Institute, 2010). There were three main components to the
initiative, one of which was a randomized control trial involving oral estrogen and progesterone.
Since that time, there have been a multitude of studies which have found that the route of
estrogen administration significantly impacts the therapy health risks associated with hormone
replacement (Tremollieres et al., 2011). In addition, these studies have found that the type of
progestin used in combination with estrogen can cause varying outcomes regarding the risk
factors related to hormone replacement (Tremollieres et al., 2011). There continues to be
confusion surrounding the use of hormone therapy.
Significance to Nursing
Menopause is a healthy and natural event in a woman's life. Some women have varying
degrees of symptoms associated with menopause. Educating women on menopause and its
symptoms can help women deal with the effects of these symptoms (Indra, 2016). Nurses are in a
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position to bring knowledge to women in menopause, and advance awareness of the evidence
about menopause and hormone use. Partnering with their patients, nurses can bring clarity to the
issue and educate using current evidence. Providing positive support and increasing a woman’s
knowledge about normal body changes can improve both life expectancy and quality of life
(Indra, 2016). Health care professionals must partner with their patients to establish trusting
relationships, inform them of the current medical evidence, and create a plan of care for their
individualized medical needs. Ultimately, any woman seeking information about menopause and
replacement hormone therapy should discuss their personal medical history with their provider to
establish and weigh their risks and benefits of hormone treatment.
Conceptual Framework
The Theory of Symptom Self-Management (TSSM) will provide a framework to the
management of symptoms of menopause and increasing a woman's self-efficacy to safely
manage menopause symptoms. This middle range theory includes characteristics of self-care and
self-efficacy, recognizing a patient's behaviors and functional status to reach their set goals. The
patient’s perceived self-efficacy, characteristics, symptoms, and health behaviors are combined
and used to develop performance outcomes. Most importantly is the collaboration of the health
care provider or practitioner and the patient; together they partner to investigate interventions to
help with empowerment and symptom self-management. Hoffman (2013) reports several studies
in which the Theory of Symptom Self-Management was used successfully for patients with
chronic and acute conditions and symptoms. “Self-management is a critical success factor for
chronic illness management and the aim is to ensure that the patient is recognized as the source
of control” (Hoffman, 2013, p 17).
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How a patient perceives themselves and their symptoms is an essential component of the
Theory of Symptom Self-Management. Developing an enhanced self-perspective using
interventions that the patient can successfully perform is how the patient can be empowered.
Also, offering observational experiences for them to see patients that are having similar health
concerns with positive outcomes, and using verbal encouragement to help set goals is the
groundwork for TSSM (Hoffman, 2013). The Theory of Symptom Self-Management
incorporates specific patient characteristics, such as their physiological and psychological
influencing factors, which is necessary when partnering with the patient to develop an
individualized plan of care.
The Theory of Symptom Self-Management can be used to understand the perceived
symptoms of menopause and how it affects the patient’s health and self-image. Partnering with
the patient to educate on symptom management, current evidence on hormone therapy, and
healthy lifestyle changes is one of the first steps in the Theory of Symptom Self-Management
model. Use of the Theory of Symptom Self-Management model with women experiencing or
transitioning into menopause will help the women understand the changes they may be
experiencing and will empower them to set healthy goals for a positive health outcome.
Summary
In this first chapter, the changes that occur with aging and the adverse effects of
menopause have been presented. Topic specific definitions were included. Detailed information
was presented on the history of hormones, and how over the years, conflicting information has
brought confusion and distrust with traditional hormone therapy. The purpose of this critical
review of the literature is to investigate current best practices, safety and efficacy, and compare
how these relate to a woman’s knowledge and beliefs of hormone therapy. The significance for
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nursing has been identified along with the Theory of Symptom Self-Management for the
application of enhancing self-efficacy for optimized patient outcomes.
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Chapter Two: Methods
The purpose of this chapter is to describe the search strategies used to identify relevant
research studies for this critical review of the literature. The topic of hormone therapy for overall
risks, benefits, and use for menopausal and postmenopausal women will be further investigated.
The literature was also reviewed for present-day knowledge, evidence, and beliefs associated
with hormone therapy. The search strategies included specific inclusion and exclusion criteria, as
well as the process and guidelines used to evaluate each study.
Search Strategies
Journal articles were gathered from the National Center for Biotechnology Information
(NCBI), National Institute of Health, Pub Med, and Cumulative Index to Nursing and Allied
Health Literature (CINAHL). Several inquiries were performed using the search terms of
postmenopausal and menopausal women, hormones, hormone therapy, transdermal, bioidentical,
and compounded hormone therapy. Particular attention was given to studies and articles that
were five years old or less, and this was advanced to include relevant studies that were older to
expand the literature findings. The years of publication for the studies and articles in this
literature review range from 2011 to 2017.
Criteria for Evaluating the Studies
Altogether 23 articles were evaluated using The Johns Hopkins Nursing Evidence-Based
Practice Model and Guidelines (Dearholt & Dang, 2012). The Johns Hopkins model identifies
levels of evidence used to analyze, synthesize, and interpret literature (Dearholt & Dang, 2012).
Each level is categorized based on the level of evidence. A randomized control trial is the highest
level, which is level I. Level I can also include systematic reviews of more than one randomized
control trial. Level II includes quasi-experimental studies which include manipulation of the
independent variable and some degree of control or randomization (Dearholt & Dang, 2012).
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Level II can also include systematic reviews of a combination of RCTs and quasi-experimental
studies. Level III includes non-experimental quantitative studies and qualitative studies which
explore a subject through interviews, surveys, or focus groups (Dearholt & Dang, 2012). Level
IV is considered non-research and includes recommendation statements from national experts
that are based on scientific evidence. Lastly, literature included in the level V category includes
opinions from individuals or professional organizations that are considered the experts of the
subject matter (Dearholt & Dang, 2012).
The standardized rating system also includes a quality rating. The highest quality is rated
A is given to studies with sample sizes sufficient for the design, congruous evidence, and clear
recommendations. A quality rating of B is considered good quality. Good quality consists of
appropriately uniform results, sample size adequate for the design of the study and some control
noted within the study, and there may have been some control noted within the study (Dearholt
& Dang, 2012). The lowest quality is C, which allows for variable sample size, evidence, and
recommendations (Dearholt & Dang, 2012).
Inclusion and Exclusion Criteria
Articles that met the inclusion criteria reported studies with menopausal and
postmenopausal women who had used or were currently using hormone therapy. Articles were
included which provided chemical and pharmaceutical information on compounded and or
bioidentical hormones. Also, articles were included to show the current use of and trends in
hormone therapy (HT). Due to non-Food and Drug Administration approved compounded
bioidentical hormone therapy, there is no way of knowing exactly how many women are actively
using compounded bioidentical hormone therapy, therefore an international study with
comparative data was included (Velentzis et al., 2016). Exclusion criteria included studies
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conducted earlier than the year 2011, studies with inconsistent results or recommendations, and
articles not pertaining to menopause and postmenopausal women. Therefore, articles that
incorporated men were excluded from this critical review of the literature. Ongoing extension
studies from two well known earlier studies, which were the Women's Health Initiative (WHI)
and Kronos Early Estrogen Prevention Study (KEEPS), were included; this provided critical
evidence that pertained to but was not limited to, current use and beliefs of hormone therapy. The
original WHI and KEEPS studies provided principle evidence on hormone use in menopausal
and postmenopausal women. These studies are seminal studies which contain critical data for the
basis of future studies. However, due to the age of these studies, the older, original studies were
not included in this literature review.
A Summary of Study Type and Quality
A total of 23 articles were identified as meeting the criteria for selection for this literature
review. Each article is organized into a matrix (see Appendix) that summarizes the content.
There are ten articles that have level I evidence, five of which are high quality (Espeland et al.,
2017; Farr, Khosla, Miyabara, Miller, & Kearns, 2013; Gleason et al., 2015; Ran et al., 2017;
Whedon, KizhakkeVeettil, Rugo, & Kieffer, 2017). Out of this level I, high quality evidence,
two of the five articles are reports of randomized control trials which were a continuation of the
original KEEPS study, rated as high quality due to the sample size, consistent results, and
adequate control (Espeland et al., 2017; Farr et al., 2013). Four articles that provide level I
evidence report studies that are good quality with reasonably consistent results and a fairly
definite conclusion (Allen, McCubbin, Loveless, & Helfer, 2014; Kocoska-Maras et al., 2013;
Nii et al., 2015; Sood et al., 2013). One of the articles that provide level I evidence was rated low
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quality due to the small sample size and missing specimens during the testing period (Pingel et
al., 2012).
Articles providing level II evidence included five quasi-experimental studies that were all
good quality due to the randomization of study assignment, consistent results, and reasonable
recommendations (Carmona-Sanchez et al., 2013; Formby & Schmidt, 2011; Połac, Borowiecka,
Wilamowska & Nowak, 2013; Ruiz & Daniels, 2014; Stephenson et al., 2013). Level III
evidence included five qualitative studies all of which were good to high quality, and one
correlational study of good quality. Of the five qualitative studies two were rated as high quality
due to large sample size, some randomization into groups, and validated survey materials
(Pinkerton & Santoro, 2015; Velentzis et al., 2016). Four of the studies that provided level III
evidence have a quality rating of B for sufficient sample size, some rater bias, and use of a nonvalidated survey tool prior to the start of the study (Canonico et al., 2012; Fishman et al., 2015;
Iftikhar et al., 2011; Thompson, Ritenbaugh & Nichter, 2017).
A position statement from the US Preventative Services Task Force was included and is
level IV high quality evidence (USPSTF, 2017). Lastly, included was one expert opinion article
from The American College of Obstetricians and Gynecologists that is level V high quality
evidence due to expertise of subject matter and definitive conclusions (The American College of
Obstetricians and Gynecologist, 2012).
Summary
This literature review was a systematic investigation into research studies to gain
knowledge about issues that women face during menopause and post-menopause. The review of
the literature investigated best practices around HT for menopausal and postmenopausal women,
and determined current evidence regarding safety and efficacy of HT. Each study was evaluated
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based on the Johns Hopkins Research Evidence Appraisal Tool for the level of strength and
quality (Dearholt & Dang, 2012). The studies were categorized and summarized using the
Evidence Synthesis Tool (Dearholt & Dang, 2012).
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Chapter Three: Literature Review and Analysis
Chapter three provides a comprehensive review and analysis of each study and article for
significant findings. A total of 23 studies and articles were gathered for information in an attempt
to answer the project practice questions: What are the current best practices around hormone
therapy use for menopausal and postmenopausal women? What is the current evidence regarding
safety and efficacy of hormone therapy? Significant findings are categorized into themes that
emerged within the literature. The strengths and weaknesses of the literature analyzed are
brought forward and discussed. Finally, each study and article is outlined within the matrix (see
Appendix).
Synthesis of Major Findings
Within the critical review of the literature, different forms of hormone replacement
therapy were investigated for the varying menopausal symptoms and common chronic medical
conditions that can appear with age. The United States Task Force recognizes that chronic
conditions or the risk of coronary heart disease, dementia, fractures, and breast cancer can all
increase with age. However, the percentage of these conditions that can be attributed to declining
estrogen is not known (USPSTF, 2017). The articles under review have differences noted in
traditional versus bioidentical and compounded bioidentical hormone therapy, as well as timing
and duration of use. Included in this literature analysis are qualitative studies that explore the
reasons women seek hormone therapy.
Menopause symptoms
Cognitive function. Menopausal symptoms due to declining estrogen, such as depression,
anxiety, hot flashes, and sleep disturbances can be devastating. Four of the level I randomized
controlled trials investigated the effect of hormone therapy (HT) on cognitive function and mood
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effects. In a study with 693 menopausal and postmenopausal women, Gleason et al. (2015)
reported oral menopausal hormone therapy does not improve cognition, although significant
improvement in anxiety and depression was noted. Both oral and transdermal routes of hormone
therapy were investigated and it was found that transdermal routes did not show benefits
(Gleason et al., 2015). To expand on this finding, Espeland et al. (2017) examined data from the
Women's Health Initiative Memory Study (WHIMS) of Younger Women, and the Women's
Health Initiative (WHI) randomized controlled clinical trials, which included older women.
Espeland et al. (2017) explained findings from both of these studies. Hormone therapy started at
menopause, with younger women, had no cognitive benefit or disadvantage. However, hormone
therapy initiated in older women resulted in a small reduction in several cognitive functions.
These changes in cognitive function were reported to last several years after the HT was stopped
(Espeland et al., 2017). Statistically significant decline in global cognitive functioning, verbal
knowledge, and verbal fluency was seen in women aged 65-79 years old that were assigned to
hormone therapy (Espeland et al., 2017). Over time the brain accommodates to the loss of
estrogen and uses other energy sources such as ketones and fatty acids. When estrogen is brought
back into the system, there is a disruption in this natural transition and cognitive function can be
impaired (Espeland et al., 2017).
Similar findings were reported in a study conducted on 200 women randomly assigned to
estrogen, testosterone, or placebo treatment for one month. Kocoska-Maras et al. (2013) declared
that hormone therapy did not increase fluency, spatial memory, or verbal ability within this study
group. The author acknowledged that other studies have shown testosterone induced positive,
although not significant, trends on spatial memory (Kocoska-Maras et al., 2013). In a systematic
review of 10 randomized control trials investigating bioidentical estrogen for the use of
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menopausal depressive symptoms in 1,028 women, Whedon et al. (2017) found no significant
improvement. The authors acknowledged their findings were consistent with the WHI study. In
all ten studies included in the systematic review, only one type of bioidentical hormone was
investigated. The author recommended that there be more studies with different types and
combinations of bioidentical and nonbioidentical HT (Whedon et al., 2017).
Menopausal symptoms. In opposition to the above finding, and to again point out that
there is conflicting evidence available to women seeking advice on alleviating menopausal
symptoms, several of the level II quasi-experimental studies showed hormone therapy improved
menopausal symptoms. Stephenson et al. (2013) showed statistically significant decreases in
depression and dysphoric moods for women who used transdermal compounded bioidentical
hormone therapy. The authors of this study support the use of transdermal compounded
bioidentical hormone therapy, with recommendations for transdermal compounded bioidentical
hormone therapy to be considered safe for menopausal symptoms. Another two level II studies
investigated the effectiveness of bioidentical hormone therapy for menopausal symptoms. One of
the studies compared transdermal and sublingual forms of bioidentical hormone therapy. Formby
and Schmidt (2011) reported after three and six months of bioidentical hormone therapy, saliva
levels of estrogen and progesterone significantly increased along with a significant fall in
menopausal symptoms as reported by the Kupperman index. The Kupperman index is a well
known, validated survey tool, which evaluates eleven of the most prevalent menopausal
symptoms. Formby and Schmidt (2011) concluded that bioidentical hormone therapy at cyclical
cycles, demonstrated positive results of both physiological and clinical outcomes. Supporting
this conclusion, Ruiz and Daniels (2014) found participants receiving sublingual hormone
replacement had the most significant reduction in menopausal symptoms. Furthermore,
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sublingual hormone therapy had faster and more significantly improved outcomes versus
transdermal treatment (Ruiz & Daniels, 2014). However, over more extended periods of use,
small improvements in mood and night sweats were seen with transdermal therapy (Ruiz &
Daniels, 2014).
Body system changes
Cardiovascular and homeostasis effects. Of the level II evidence, the main focus of four
of the studies was cardiovascular effects, which included inflammation, cholesterol, and clotting
factor results in women who were currently or had ever used hormone therapy. Stephenson et al.
(2013) examined not only the long-term effects of transdermal application of compounded
bioidentical hormone therapy on depression, but also cardiovascular markers, which included
inflammatory and immune signaling factors in menopausal and postmenopausal women. The
study was conducted over three years, which in this context implies the definition of long-term.
Within this study, statistically significant changes in inflammatory and immune signaling factors
were seen with transdermal hormone therapy (Stephenson et al., 2013). Also, along with the
other benefits of compounded bioidentical hormone therapy shown in this study, fasting glucose
and triglycerides decreased significantly. Contradictory to the prior study, Canonico et al. (2012)
found that higher levels of estrogen are associated with higher levels of fibrinogen, which can
promote inflammation in postmenopausal women.
Połac et al. (2013) investigated oral versus transdermal hormone therapy, and reported
after six months that fibrinogen levels were higher, and thrombin activity was statistically higher
in the oral hormone therapy group. Although both transdermal and oral hormone therapy groups
showed an increase in fibrinogen levels, the oral hormone therapy group had the most significant
increase. The author's recommendations around hormone therapy for menopausal treatment are
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to choose the safest product with the lowest known changes in coagulation and fibrinogen
effects. Also, more studies are needed to evaluate the efficacy and safety of hormone therapy
(Polac et al., 2013). These findings are an essential point to review because of the many different
forms of hormones on the market, and the unique physiologic make-up of each woman. An
evaluative pharmacy study on compounded bioidentical hormones found skin physiology, blood
flow, and hormone metabolism can all affect hormone serum levels (Sood et al., 2013).
These findings can also contribute to more confusion for women when trying to
understand the evidence that exists on hormone products. Nii et al. (2015) investigated the
hepatic effects of three different types and routes of estrogen administration on cholesterol
production. The authors of this study found different hepatic effects with different routes and
doses of estrogen (Nii et al., 2015). These different effects may be associated with the risk of
cardiovascular disease because of the impact on low density lipoprotein (LDL), high density
lipoprotein (HDL), and free radical production (Nii et al., 2015). Allen et al. (2014) found that
during stress there was a significant increase in systolic blood pressure across all study groups.
However, the most significant increase was in the hormone therapy/placebo group. The smallest
increase was seen in the hormone therapy/naltrexone group. This study attempted to explain the
endogenous opioids relationship and the effects of estrogen during stress. Allen et al. (2014)
concluded that this relationship correlates with and elevates the coronary heart disease risk when
taking hormone therapy.
Bone and collagen turnover. Farr et al. (2013), in a KEEPS trial sub-study of seventy-six
menopausal women, established that cortical bone is responsive to estrogen, and estrogen
replacement therapy prevents the loss of cortical bone. Within this study, transdermal and oral
conjugated estrogen were trialed. The authors recommended that more studies were needed to
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investigate the site and route-specific forms of estrogen (Farr et al., 2013). Also, Ran et al.
(2017) in a five-year study of 120 women in menopausal transition found a significant increase
in bone mass density in oral hormone replacement groups in conjunction with a daily exercise
routine. The increase in bone density was seen in the first two years, then it continued to
decrease. However, at the end of the fifth year, bone mass density remained higher than before
treatment for the hormone replacement groups (Ran et al., 2017). Similar findings were
described in a study by Pingel et al. (2012), which investigated collagen stimulation effects in
women on replacement hormone therapy and exercise. It was reported at day five of treatments
with transdermal hormone therapy and exercise that serum collagen markers were significantly
higher. This increase in the collagen marker effect was reported to expand with increased
duration of use of the transdermal hormone therapy (Ran et al., 2017). A recommendation
statement from USPSTF (2017) addressed hormone therapy for the prevention of
postmenopausal osteoporosis. Individual characteristics and specific risk factors for chronic
conditions such as osteoporosis should be advised using harm versus benefit ratio. Also,
hormone therapy should be prescribed at the lowest dose for the shortest duration (USPSTF,
2017).
Breast density and risk of breast cancer. Due to several of the articles referencing an
increased risk of breast cancer when using hormone therapy, a study assessing the effects of long
term hormone therapy on breast density was included. Carmona-Sanchez et al. (2013) asserted
increased breast density could hide or make it difficult to detect a small mass and is associated
with the increased risk of breast cancer. This study was conducted over five years, which in this
instance is considered long-term. The study included 165 postmenopausal women receiving
transdermal hormone therapy. All study participants received estrogen, which was beta-estradiol
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at the same strength. The study participants with a uterus also received progesterone, divided
between two different forms and strengths. Mammogram x-ray reports were done at baseline,
one year, and five years. Although all women in this study received transdermal hormone
therapy, three different combinations of transdermal hormone therapy were studied. At one and
five years, all women in the study showed increased breast density. Women on combined
hormone therapy showed the most significant increase in breast density as compared to women
on estrogen therapy alone (Carmona-Sanchez et al., 2013). Women on a cyclic combined
hormone therapy had the most significant increase in breast density at five years (CarmonaSanchez et al., 2013). These findings are consistent with the USPSTF recommendation
statement. Combined estrogen and progesterone was evaluated with a moderate harm risk for
invasive breast cancer (USPSTF, 2017).
The use of bioidentical hormones
Movement toward CBHT. The shift towards compounded bioidentical hormone therapy
(CBHT) is thought to be an effort to seek improved health, well-being, and control due to choice
(Iftikhar et al., 2011). There are regulated Food and Drug Administration approved bioidentical
forms of hormone therapy, but women and some physicians are drawn to the compounded
bioidentical hormone therapy. Thompson et al. (2017) explain a push-pull phenomenon in
women who are seeking hormone therapy for menopausal symptoms. Push meant women are
pushed to compounded bioidentical hormone therapy because of frustration with the conflicting
hormone therapy information, lack of trust with the medical community, and media accounts of
cancer from traditional hormone therapy. Pull meant women are pulled to use compounded
bioidentical hormone therapy due to the perception it is safer, the belief it is effective in
controlling their symptoms, and longing for individualized treatment (Thompson et al., 2017).
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These findings are similar to the results of a study by Fishman et al. (2015), which investigated
clinicians’ practice and views of aging and medicine, and patient perceptions and experience
with anti-aging therapies. Women are drawn to compounded bioidentical hormone therapy and
the clinicians who prescribe it because they felt like the clinicians listened to them and validated
their concerns and menopausal symptoms (Fishman et al., 2015). The clinicians that prescribed
compounded bioidentical hormone therapy regarded themselves as good listeners, and felt they
have the ability to care holistically (Fishman et al., 2015).
Safety and purity of CBHT. Compounded bioidentical hormones have not been
adequately studied. Also, there is not the same Food and Drug Administration approval or
regulation for these types of hormone therapy products (Sood et al., 2013). This literature review
includes five level III qualitative studies that all analyze what percentage of women use
compounded bioidentical hormone therapy, why compounded bioidentical hormone therapy is
chosen, and what the current beliefs are around compounded bioidentical hormone therapy and
traditional hormone therapy. This information is essential due to the fact that compounded
bioidentical hormone therapy is not FDA regulated because it is not a standardized
pharmaceutical product. Conventional medical and science's general opinion is that compounded
bioidentical hormone therapy has the same risk and benefits of standard hormones (Thompson et
al., 2017). Without the mandated regulations of the Food and Drug Administration, there is
concern about the quality and safety of compounded bioidentical hormone therapy. Also, dose
ranges are not controlled; this leaves compounded bioidentical hormone therapy users vulnerable
to substandard dosing, which highlights other concerns around cancer (Thompson et al., 2017).
Advertising for compounded bioidentical hormone therapy acclaims it to be natural, therefore
there is an underlying misrepresented claim of safety (Iftikhar et al., 2011). An article that
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provides level V evidence included in this review is an expert opinion article from The American
College of Obstetricians and Gynecologists (2012). Within this article, conclusions and
recommendations are outlined about compounded bioidentical hormone therapy use. Evidence is
lacking to support claims of compounded bioidentical hormone therapy use. Also, efficacy and
safety based on salivary, serum, or urine testing are deficient (The American College of
Obstetricians and Gynecologist, 2012). There is an increased risk associated with compounded
bioidentical hormone therapy in regard to product strength and sterility. The packaging of the
compounded bioidentical hormone therapy product lacks safety data that should be included
(The American College of Obstetricians and Gynecologist, 2012).
Numbers and knowledge of hormone therapy. In an attempt to approximate numbers of
compounded bioidentical hormone therapy users, Velentzis et al. (2016) surveyed women of the
Medicare enrollment database from Australia's universal health plan. It was found roughly
between 2% and 15% of women who chose hormone therapy also chose bioidentical hormone
therapy. This information is critical when looking at the understanding and knowledge about
hormone therapy of women who chose compounded bioidentical hormone therapy. Pinkerton
and Santoro (2015) estimated that between one and 2.5 million United States women use
compounded bioidentical hormone therapy, even though not all understand or are aware of the
difference between Food and Drug Administration approved or compounded hormone therapy.
Pinkerton and Santoro (2015) identified that of the women who choose compounded bioidentical
hormone therapy, between 14% and 27%, did not know if their current hormone therapy was
compounded bioidentical hormone therapy, and 76% did not answer questions about
compounded bioidentical hormone therapy correctly. Providers should be educating and advising
patients on both the risks and the benefits of hormone therapy, the information should be
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provided on the differences between Food and Drug Administration approved and compounded
bioidentical hormone therapy, and caution should be taken when prescribing compounded
bioidentical hormone therapy (The American College of Obstetricians and Gynecologist, 2012).
Strengths of the Most Salient Studies
All articles and studies have been evaluated for level and quality of evidence, based on
the Johns Hopkins Guidelines (Dearholt & Dang, 2012). Included in this critical review of the
literature are several level I, II, and III research studies with high and good quality ratings in an
attempt to answer the practice questions posed for this project. Espeland et al.’s (2017)
systematic review with meta analysis contains data derived over many years from 2008–2015, as
well as evidence which was found to be consistent with other studies. The second salient study
addressed the different effects between oral versus transdermal hormones. Gleason et al. (2015)
investigated data from over 600 women. The women were randomized into three different
groups, which were oral hormone therapy, transdermal hormone therapy, and a controlled
method with a placebo. This investigation was conducted over four years and produced data with
consistent results, provided uniform recommendations, used good references, and had adequate
comparisons to other large studies. A third salient study identified the usage and the knowledge
of the various hormone therapies within the United States. Pinkerton and Santoro (2015) used a
cross sectional internet survey method to interview women who had either previously or
currently used hormone therapy. Using the cross sectional method, with large numbers of
participants, enabled the results to be compared for consistency.
Weaknesses of the most Salient Studies
Pingel et al.’s (2012) randomized control trial reported missing specimens during the
testing period, which could have had an effect on the overall study outcome. Prior co-morbities
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were reported within the study, however, the relationship of health related co-morbities and the
use of hormone therapy cannot be ruled out or entirely explained when reporting estrogen and
fibrinogen levels (Canonico et al., 2012). Inconsistent study results with over generalized
recommendations were given from a quasi-experimental study done to evaluate the efficacy of
bioidentical transdermal hormones that was conducted on a small sample size of 29 women
(Formby & Schmidt, 2011). In one of the qualitative studies, a survey tool was not validated
prior to its use in the study (Iftikhar et al., 2011). Lastly, several of the studies reported that the
study participants were a generalization of the greater population, when it did not appear that this
was true (Gleason et al., 2015; Pinkerton & Santoro, 2015; Ruiz & Daniels, 2014; Thompson, et
al., 2017; Velentzis et al., 2016).
Summary
Within this chapter, 23 articles and studies were reviewed for information about risk and
benefits, current knowledge, beliefs, and practices regarding hormone therapy and compounded
bioidentical hormone therapy use. The significant findings were detailed and categorized into
evidence levels according to the Johns Hopkins Nursing Evidence-Based Practice: Model and
Guidelines (Dearholt & Dang, 2012). Strengths and weaknesses were outlined and allocated.
Lastly, each article was organized into a matrix (see Appendix) that summarized the content.
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Chapter Four: Discussion, Implications, and Conclusions
The focus of this literature review was to search for an understanding around menopause,
the use of hormone therapy for menopausal symptoms, and possible prevention of chronic
conditions that appear as a woman ages. This literature review also revealed current best
practices for hormone replacement therapy, and evidence about safety and efficacy of
bioidentical, compounded bioidentical, and traditional hormone therapy. The practice questions
to guide this critical review of the literature were: What are the current best practices around
hormone therapy use for menopausal and postmenopausal women? What is the current evidence
regarding safety and efficacy of hormone therapy? In this chapter current trends and gaps in the
literature are discussed, in addition to recommendations for further research. Implications for
nursing practice to help educate and partner with patients and the use of the Theory of Symptom
Self-Management are applied.
Synthesis of the Literature
Over the last several decades, knowledge about hormone replacement therapy has
evolved. Information from ongoing seminal research studies has revealed details about
traditional hormone therapy. In an effort to continue to look for applications to help women
through the menopause transition and some of the devastating symptoms that go along with that
transition, alternative hormone therapy, which is bioidentical and compounded bioidentical
hormone therapy, was developed. Misconceptions about this alternative have become apparent
due to unproven claims and celebrity endorsements. Through the evaluation of the literature, the
information regarding traditional, bioidentical, and compounded bioidentical hormone therapy
was identified and synthesized to answer the practice questions.
Best Practices. Menopausal symptoms which include depressive symptoms, anxiety, hot
flashes, and sleep disturbances can be devastating and have lifelong consequences if not
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adequately addressed. Based on the severity of the symptoms, a woman’s quality of life can be
adversely affected. Formby and Schmidt (2011) reported a significant fall in the Kupperman
index and asserted that bioidentical hormone therapy demonstrates positive results of both
physiological and clinical outcomes. The evidence is confusing; Gleason et al. (2015) identified
oral hormone therapy does improve anxiety and depression however, transdermal bioidentical
hormone therapy does not show benefits. Hormone therapy can be used for treatment of
menopausal symptoms in women transitioning into menopause. Each form of hormone therapy,
whether it is traditional or bioidentical, carries the same health risks. Therefore, the use of
hormones should be prescribed at the lowest dose for the shortest duration possible for
attempting to control menopausal symptoms.
As a woman ages, the risk of cardiovascular disease increases (World Health
Organization, 2017). There is conflicting evidence available on benefit versus harm for estrogen
therapy and coronary heart disease. The USPSTF (2017) brings to our attention the observational
evidence about the protective effects of hormone therapy for heart health in younger women,
however, also points out several seminal studies that have shown an increased risk of coronary
heart disease due to hormone therapy in older postmenopausal women. Data reported from
randomized clinical trials show no benefit of hormone therapy when used for cardiovascular
disease in older postmenopausal women, rather a harmful effect due to an overall decline in the
artery walls and build up of a fatty coating and scar tissue that increases the risk of thrombosis
and decreased coronary circulation (USPSTF, 2017). Oral hormone therapy is metabolized
through the liver, which creates a hepatic effect that increases cholesterol and coagulation
parameters (Polac et al., 2013; Nii et al., 2015). These findings are associated with an increased
risk of cardiovascular disease, which is predominantly higher when other co-morbidities exist
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(Polac et al., 2013). Hormone replacement therapy should not be used to treat chronic
conditions.
Farr et al. (2013) found that replacement hormone therapy significantly prevented loss of
cortical bone. The United States Preventative Services Task Force (USPSTF) published a broad
recommendation statement about the use of estrogen and progestin for chronic conditions in
postmenopausal women. Within this recommendation statement, several studies are reviewed for
evidence. The benefits are noted for the use of estrogen for postmenopausal osteoporosis.
However, they go on to say that treatment should be prescribed at the lowest dose and for a brief
period (USPSTF, 2017). Within their published report, The United States Preventative Services
Task Force recommends other alternative medications and healthy living choices that do not
carry the same health risks as hormone therapy for the use of postmenopausal osteoporosis
(USPSTF, 2017). The individual benefits and risks need to be weighed each time a woman is
seeking advice on menopause or any inherent genetic disease process.
Some of the studies based their findings on salivary lab results of women who were on
the hormone replacement therapy. The American College of Obstetricians and Gynecologist
(2012) point out concerns for safety and efficacy based on salivary testing and state “there is no
evidence that hormonal levels in saliva are biologically meaningful and salivary testing does not
currently offer an accurate or precise method of hormone testing” (p. 413). Recommendations
for the use of traditional and transdermal “bioidentical” Food and Drug Administration approved
hormone therapy for primary prevention of chronic conditions is discouraged due to the
associated harm that they may cause. These harms and health risks are coronary heart disease,
invasive breast cancer, thromboembolic events, decreased cognitive impairment, and gallbladder
disease (USPSTF, 2017).
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Current evidence regarding safety and efficacy. Literature articulated the theme of
safety and purity of traditional, bioidentical, and compounded bioidentical hormone therapy. In a
study assessing the effects of endogenous sex hormones on fibrinogen levels to estimate the
effects of hormone therapy, Canonico et al. (2012) found a positive correlation of fibrinogen
levels and estrogen levels, and significant interactions of total oestradiol (E2) with fibrinogen
levels (p<0.001). Canonico et al. (2012) found the correlation of oestradiol (E2) with fibrinogen
to be significantly more positive in women with an elevated body mass index (BMI) (p = 0.02).
Increased fibrinogen levels are related to inflammation and are directly related to increased risk
for cardiovascular disease (Canonico et al., 2012). Another safety concern around traditional
hormone therapy is that of breast cancer. Increased breast density is a standalone risk factor for
breast cancer. Carmona-Sanchez et al. (2013) reported a significant increase at five years in
breast density in women on combined hormone therapy versus those on estrogen therapy alone
(p<0.009). After five years of use, women on a cyclic combination of traditional hormone
therapy had a significant increase in breast density versus women on continuous combined
therapy (p<0.039).
Some traditional and transdermal “bioidentical” forms of hormone therapy have been
approved for menopausal symptom management and are regulated by the Food and Drug
Administration. Whedon et al.’s (2017) systematic review of ten different studies which
compared bioidentical hormones with placeboes and included over 1,208 women, evaluated
primary outcomes of improved depressive symptoms as measured by a validated depression
scale. It was reported that there was no significant change in depressive symptoms in women
who used bioidentical hormone therapy as compared to placebo (SMD-0.02, 95% CI -0.41 to
+0.38). However, more than half of the subjects included were older postmenopausal women.
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Adverse effects included increased vaginal bleeding. Whedon et al. (2017) reported that most of
the studies included in the systematic review were of short duration and serious adverse effects
were unable to be captured. In a study assessing the effects of bioidentical hormone therapy on
menopausal symptoms of women in the menopause transition, Formby and Schmidt (2011)
reported that after three and six months of use, saliva levels of estradiol and progesterone
significantly increased as compared to baseline levels (p<0.01). Likewise, after six months of
bioidentical hormone therapy treatment it was shown that the Kupperman index decreased to a
value of 7 as compared to baseline value of 30 (Formby & Schmidt, 2011).
Other hormone therapy applications, such as compounded bioidentical hormone therapy,
have no Food and Drug Administration approval. Due to the lack of Food and Drug
Administration approval, guidelines for quality and safety are limited. Compounded bioidentical
hormone therapy is not subjected to the same standards and lacks the regulatory testing of
quality, purity, and potency (Bhavnani & Stanczyk, 2012). In fact, due to the lack of regulation
of the compounded bioidentical hormone therapy, there have been proven cases of contamination
by viruses, bacteria, and other pathogens (L’Hermite, 2017). Bhavnani and Stanczyk (2012)
identify a report from the Food and Drug Administration Division of Prescription Drug
Compliance and Surveillance where 34% of the products failed one or more standard quality
tests; also nine out of ten products failed because the actual active ingredient was less than
reported on the label. When products lack Food and Drug Administration approval, there is no
class labeling or official labeling, which means compounded bioidentical hormone therapy is
exempt from providing contraindications and warnings on the labels (The American College of
Obstetricians and Gynecologists, 2012). The label of natural on compounded hormones does not
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make them safer than the Food and Drug Administration approved hormones, they carry the
same risks as other hormone preparations (“2 points to ponder”, 2016).
Current Trends
Due to the conflicting information about safety and efficacy, women are looking for an
alternative. Supporters of custom-compounded bioidentical hormone therapy make unconfirmed
claims that compounded bioidentical hormone therapy is safer and has fewer side effects
(Bhavnani & Stanczyk, 2012). Thompson et al. (2017) found that women are frustrated and lack
trust in traditional medicine; they felt clinicians who prescribed compounded bioidentical
hormone therapy listened to them, and did not discount their symptoms or concerns. Also, they
found that women felt empowered when choosing compounded bioidentical hormone therapy
(Thompson et al., 2017). Fishman et al. (2017) point out that a "predominant complaint of
women is that they felt misunderstood, minimized, and even dismissed" (p. 10).
Velentzis et al. (2016) conducted a survey study on Australian women to assess and
estimate the current use of menopause hormone therapy. It was found that in 2013, the estimated
use of hormone therapy in Australia was approximated at thirteen percent. In the United States,
the use of traditional hormone therapy has decreased due to adverse findings from several
terminal studies. However, the use of custom compounded bioidentical hormone therapy is
reported to have increased. The increase may be due to unproven health claims, celebrity
endorsements, and physician and pharmacist’s authorization while benefiting economically
(Pinkerton & Santoro, 2015). In the US, prescriptions for compounded bioidentical hormone
therapy cannot be tracked because the Food and Drug Administration does not regulate it; this
means the actual number of compounded bioidentical hormone therapy users is unknown.
Pinkerton and Santoro (2015) reported that approximately one to two and a half million US
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women aged forty or older use compounded bioidentical hormone therapy, and spend
approximately one to two billion US dollars each year on compounded bioidentical hormone
therapy. Of the women surveyed, many reported not knowing that the Food and Drug
Administration does not regulate compounded bioidentical hormone therapy, and several did not
know if the hormone therapy they were using was compounded bioidentical hormone therapy or
not (Pinkerton & Santoro, 2015). In another finding from a study done by Fishman et al. (2015),
a surveyed participant stated: “they are more likely to use compounded bioidentical hormone
therapy because it cannot be assigned a patent. Therefore, the pharmaceutical industry cannot
make money from preparing it” (p. 13). This statement is entirely false and contrary to the actual
truth of this multi-million dollar industry.
Gaps in the Literature
Due to the lack of Food and Drug Administration approval for compounded bioidentical
hormone therapy, there are few rigorous studies done that include this form of hormone therapy.
The well known terminal studies included bioidentical and traditional hormone therapy, although
both of these forms had Food and Drug Administration approved. Two of the level III qualitative
survey studies used convenience samples and lacked randomization of sample subjects, limited
generalization to the population at large (Pinkerton & Santoro, 2015; Thompson et al., 2017).
The USPSTF calls to our attention, a predominant number of the studies do not include different
races or ethnicities (2017). The timing of initiation of hormone therapy has been mentioned, but
there are conflicting data to support either harm or benefit, and it is not well understood
(Espeland et al., 2017; USPSTF, 2017). Many of the studies do not take into account other comorbidities of the participants, which could enhance the adverse effects of the HT. As in the
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study by Canonico et al. (2012), it was found that overweight women had a more significant
increase in fibrinogen levels than the leaner study participants.
Implications for Nursing Practice and Education
The evidence has pointed out the inconsistency and confusing information that is
available to women about hormone therapy. Nurses working with women clients need to keep
up-to-date on current data and research available to adequately inform and educate women on the
efficacy and safety of hormone therapy. Also, it is essential to educate women on the changes
and symptoms that can take place while transitioning through menopause. Across the board,
every woman will experience menopause; however, not every woman will experience it the same
way. Different cultures have divergent opinions and meanings for menopause (Indra, 2016).
Helping women to understand the changes that their bodies are going through will equip them
with knowledge so they can meet and react to the challenges of menopause positively. It is
critical that women are offered current information on menopause and instructed on resources
available to help with the symptoms with which they may be confronted. Nurses can inform on
healthy lifestyle changes or modifications to manage menopausal symptoms. Nurses can ensure
women have a voice in their care and that their concerns are heard. The topic of menopause, the
transitional symptoms, and chronic conditions that women may experience with age need to be
discussed and thought of as preventative medicine. How devastating are the symptoms? Women
need to be informed of their choices and the evidence that exists. What types of hormone therapy
are available? Even when the evidence can be confusing and conflicting, women need to be
heard and educated on the benefits versus the harm of every therapy prescribed. Each option
should be explored in partnership with the patient.
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Recommendations for Nursing Research
Most of the studies included in this literature review recommend that more research
needs to take place to evaluate the safety and efficacy of hormone therapy. It is essential to take
into account the current recommendations from the United States Preventative Services Task
Force, which advises against the use of hormone therapy as the primary prevention of chronic
conditions in postmenopausal women (USPSTF, 2017). It is known that women are continuing
to use hormone therapy. Increased research is needed to understand why they are choosing
compounded bioidentical hormone therapy. Knowing why women are choosing hormone therapy
or compounded bioidentical hormone therapy would offer information on how health care can
integrate other practices or therapies to help women during this challenging life transition.
Interventional nursing research is needed to look at alternatives to hormone therapy and the
efficacy of substitute therapies. Of the users of hormone therapy, it was reported that the duration
of use was significantly more than five years, which sparked recommendations to continue to
monitor due to prolonged exposure and consequent health risks (Velentzis et al., 2016). More
studies are needed to test compounded bioidentical hormone therapy preparations and the safety
of use over extended periods.
Integration and Application of the Theory of Symptom Self-Management
Some of the symptoms of menopause can be devastating; depression and trouble sleeping
can lead to other chronic conditions. Stephenson et al. (2013) found that stress and depression in
women have been associated with declining health status, and have been shown to increase their
risk of cardiovascular disease. Every woman experiencing menopausal symptoms reacts
differently; some may perceive their symptoms as a threat or an unhealthy warning. Symptoms
can be physical (hot flashes) as well as psychological (anxiety and depression). The Theory of
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Symptom Self-Management (TSSM) can help care providers to implement positive self-efficacy
for symptom self-management (Hoffman, 2013).
Using TSSM, understanding women’s perceived self-efficacy is a crucial first step in
identifying and addressing functions that can be applied to set goals for wellness and
empowerment. A woman’s menopausal symptoms may be sleep disturbances and anxiety.
Addressing the physiological (menopausal transition and hormone fluctuation) and psychological
(fatigue and anxiety symptoms), and how these symptoms may be affecting her day-to-day
routine is part of the TSSM model. Sharing information and evidence on managing menopausal
symptoms to help her set individual goals to handle her symptoms is the second step for
Symptom Self-Management. Listening to the patient’s perceptions of their ability to manage
their symptoms, the nurse and care provider can direct the patient to set goals that are perceived
by the patient as attainable to achieve symptom self-management. Each time the patient achieves
a set goal and realizes the decreased negative symptoms will empower and encourage her for a
positive health outcome.
The Theory of Symptom Self-Management can be applied to symptomatic menopausal
women to help inform and empower them to make healthy lifestyle choices for symptom
management. The nurse or healthcare provider needs to educate on non-hormonal treatments and
lifestyle changes such as exercise, diet, and stress reduction. Pinkerton and Santoro (2015)
reported that a large number of menopausal women did not seek hormone treatment, instead
made lifestyle changes that they reported as producing moderate to significant relief of
symptoms. Partnering with the patient to identify their symptoms and behaviors that they can
modify (lifestyle changes), then applying it to functional goals and expected outcomes such as
diet modification and exercise, will empower them to self-manage their symptoms.
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Another enhancing intervention for self-efficacy and symptom self-management is to
share professional websites such as the North American Menopause Society (NAMS) where the
patient could find evidenced-based literature and information on menopause, healthy symptom
management, and Food and Drug Administration approved pharmaceutical hormone therapy
information. Support group engagement could help the patient to observe secondary experiences
that would also promote self-efficacy and symptom self-management.
Many of the studies done to identify use, trends, and reasons why women choose
hormone therapy or compounded bioidentical hormone therapy for the management of
menopausal symptoms suggested a need for women to feel listened to, supported, and
empowered (Pinkerton & Santoro, 2015 & Velentzis et al., 2016). The Theory of Symptom SelfManagement promotes a trusting relationship and an engaged partnership with the patient to
develop individualized health and symptom management with goal-oriented plans to empower
them to optimal health outcomes (Hoffman, 2013).
Conclusion
This chapter discussed the common themes that emerged while conducting a critical
review of the literature to answer the practice questions from chapter one. While it was shown
that there are a variety of reasons women may choose to use hormone therapy, it also became
evident that there is much confusing information available to the general public about hormone
therapy, bioidentical, and compounded bioidentical hormone therapy. Many women are not well
informed about the differences or the efficacy of the different forms (Pinkerton & Santoro,
2015). Governmental and professional organizations advise women to consult their physician or
care provider when looking for information about hormone therapy. These organizations also
provided strict recommendations for treatment, if necessary, due to family genetic osteoporosis
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or severe menopausal symptoms, which include that treatment should be at the lowest dose for
the shortest duration of time (USPSTF, 2017; The American College of Obstetricians and
Gynecologists, 2012). Nursing implications were recommended for educating women on
changes they may experience during menopause, current evidence of hormone therapy, and
healthy lifestyle changes to help with the menopausal symptoms. Due to the growing popularity
in compounded bioidentical hormone therapy, there is a need for research to evaluate the safety
and efficacy of its use. The Theory of Symptom Self-Management was applied to show the
importance of partnering with women to empower them with knowledge and evidence to help
them live a long healthy life.
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Appendix: Evidence Synthesis Matrix
Source: Allen, A. J., McCubbin, J. A., Loveless, J. P., & Helfer, S. G. (2014). Effects of
estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women.
Journal of Behavioral Medicine, 37(1). doi: 10.1007/s10865-012-9468-3
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Randomized Placebo
SBP significantly
Strengths:
To explore if
controlled trial
increased across all
Randomization and
hormone
groups but the greatest
placebo used. Verified
Method: Participants
replacement
increase was in the
and validated
therapy has an
were blinded to the
HRT/placebo group.
instrument used for
drug versus placebo
effect on blood
Smallest increase was
testing.
pressure while
administration.
seen in the
under stress, also
Participants were given HRT/naltrexone group.
12 week supply of
comparing this to
opioid antagonist
HRT or placebo.
results within the
same group of
SBP, DBP, MAP, and
HR were measured at
participants.
baseline, during
Conclusion:
stressor task periods,
Sample:
Study provides support
and at a 10 minute post for the correlation
42 women total
Limitations:
27 HRT
stress recovery period. between hormones and Did not allow for
15 placebo HRT
younger participants so
endogenous opioid
Instruments: Critikon function during stress.
these results may be
Dinamap Model 8100
Setting: Quiet,
different in younger
temperature
Vital Signs Monitor
women.
controlled room.
was used to measure
HR, systolic, diastolic
and mean arterial
Johns Hopkins
Evidence
pressures.
Appraisal
A 10 minute computer
based arithmetic
Level of
Evidence:
stressor with randomlyLevel I
generated arithmetic
problems.
Quality: B
Author Recommendations: Further studies are needed to address the differences that age may
have on these results. Further studies are needed to investigate the merit of the findings within
this study due to increased cardiovascular reactivity with older women.
Implications: The study’s findings show how complex the effects of sex hormones are on the
body systems.
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Source: Canonico, M., Brailly-Tabard, S., Gaussems, P., Setiao, J., Rouand, O., Ryan, J.,… &
Scarabin, P. (2012). Endogenous oestradiol as a positive correlate of plasma fibrinogen among
older postmenopausal women: A population based study (the three-city cohort study). Clinical
Endocrinology, 77(6), 905-910.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Correlational study
Positive correlation
Strengths:
Assess the effects
between levels of
of sex hormones
Method: Fasting blood estrogen and levels of
Number of participants
on the fibrinogen
samples of Fibrinogen, fibrinogen.
in the study.
levels and those at total E2 (estrogen),
No association shown
higher
total T (testosterone)
cardiovascular and and SHBG (sex
between Testosterone,
dementia risk.
hormone binding
sex hormone binding
globulin) from
globulin and fibrinogen.
Sample/Setting:
randomly selected
Overweight women had
602
participants.
postmenopausal
higher levels of
estrogen and fibrinogen
women, aged 74 – Instrument: Fasting
78 years old.
blood samples of
as compared to lean
Limitations:
women.
citrated and EDTA
Could not rule out or
Johns Hopkins
plasmas obtained.
explain the
Evidence
Fibrinogen was
Conclusion:
relationship to other
Appraisal
measured using the
Higher levels of
health related
citrated plasma. Total estrogen are associated comorbidities with the
Level of
E2, total T, and SHBG with higher levels of
levels of estrogen and
Evidence:
were measured using
fibrinogen which can
fibrinogen.
Level III
the EDTA plasma.
promote inflammation
Quality: B
in postmenopausal
women.
Author Recommendations:
More studies are needed to explore plasma fibrinogen and estrogen levels with respect to cardiac
disease.
Implications: Fibrinogen is a factor in the coagulation process. Fibrinogen is also an
inflammatory marker.
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Source: Carmona-Sanchez, E., Duadros Lopez, J. L., Cuadros Celorrio, A. M., Perez-Roncero,
G., Gonzalez Ramirez, A. R., & Fernandez Alonso, A. M. (2013). Assessment of mammographic
density in postmenopausal women during long term hormone replacement therapy.
Gynecological Endocrinology, 29(12), 1067-1070. doi: 10.3109/09513590.2013.831831
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Quasi-experimental
At one and five years all Strengths:
To assess the
observational study.
women showed
Number of participants
effects of long
increased breast density. and number of followMethod: Mammogram Women on combined
term hormone
up years.
HRT therapy showed a
replacement
x-ray reports done at
baseline, one year, and greater increased breast
therapy on
density than women on
mammographic
five years.
(breast) density.
estrogen therapy alone.
Women on a cyclic
combined HRT therapy
Sample/Setting:
had the most significant
Sample: 165
increase in breast
postmenopausal
Limitations:
Instrument: Standard density at five years.
women receiving
Was non-randomized
mediolateral and
transdermal
study. Only used one
hormone therapy. craniocaudal
form of progestin in
mammogram
Setting:
HRT combination. Did
Menopause Unit
projections obtained
not include diet of
of the San Cecilio using X-ray equipment Conclusion:
participants which
at one and five years.
Significant increase in
Clinical
could have had an
breast density after
University
effect on steroids
combined estrogen and within the body and
Hospital, Granada,
medroxyprogesterone
breast characteristics.
Spain.
acetate therapy than
after estrogen alone.
Johns Hopkins
This finding is more
Evidence
frequently seen at five
Appraisal
years of combined HRT
treatment.
Level of
Evidence:
Level II
Quality: B
Author Recommendations: Increased breast density is more frequent in women on combined
HRT therapy than women on estrogen therapy alone.
Implications: Increased breast density could hide or make it difficult to detect a small mass.
Also, increased breast density is associated with the increased risk of breast cancer.
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Source: Espeland, M. A., Rapp, S. R., Manson, J. E., Goveas, J. S., Shumaker, S. A., Hayden, K.
M.,… & Resnick, S. M. (2017). Long-term effects on cognitive trajectories of postmenopausal
hormone therapy in two age groups. Journals of Gerontology: Medical Sciences, 72(6).
doi:10.1093/Gerona/glw156
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Systematic review with Slight and not
Strengths: Large
Long term follow- meta-analysis
significantly higher
study with many
up of two studies
cognitive scores of
participants over long
Method: Yearly phone younger women
to determine if
term period.
there are cognitive interviews, data
assigned hormone
differences or late derived from 2008 –
therapy. Placebo group
effects between
2015.
of older women had
placebo and
significantly better
intervention
score performance of
groups.
global cognitive test.
Instruments: East
Sample:
Boston Memory Test,
Limitations:
Two large studies: Oral Trail Making
Test, Verbal FluencyWomen’s Health
Data were derived
Animals Test, and
from volunteers so this
Initiative = 1,376
Digit Span Test.
may not be a good
women aged 50 –
56 years old, and
All data between
representation of the
2,880 aged 65-79
intervention and
general population.
placebo groups were
Conclusion:
years old.
Small detectable
compared using
Setting: 40
Hormone therapy
differences are
academic centers
Statistical methods.
started at menopause, in reported, cannot rule
younger women, has no out unmeasured factors
Johns Hopkins
cognitive benefit or
that may have
Evidence
attributed to these
damage. Hormone
Appraisal
therapy started in older differences.
women, results in small
Level of
reduction in several
Evidence:
cognitive functions that
Level I
have been shown to
persist.
Quality: A
Author Recommendations: Further assessment is needed to evaluate safety of hormone use in
younger women.
Implications: Hormone use in older women has led to cognitive deficits that remain after
medications are discontinued. As a woman ages, the brain adapts to loss of estrogen, and a
secondary energy source is used. If estrogen is reintroduced at this time it will disrupt cognitive
function.
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Source: Farr, J. N., Khosla, S., Miyabara, Y., Miller, V. M., & Kearns, A. E. (2013). Effects of
estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure
in recently postmenopausal women. The Journal of Clinical Endocrinology & Metabolism,
98(2), 249-257. doi: 10.1210/jc.2012-3406
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Randomized
Menopausal hormone
Strengths:
To examine if
Controlled Trial – sub
therapy significantly
Used 3 dimensional
estrogen has an
study.
prevented loss of
imaging with
effect on cortical
cortical bone.
computed tomography
Method: Doubleand trabecular
Menopausal hormone
(QCT) which has
blinded, four year
bone.
therapy did not prevent much more validity
study, 31 subjects
decrease in trabecular
than other studies that
Sample:
received a placebo, 20 bone parameters.
used x-ray.
women received
76 menopausal
conjugated equine
women who had
estrogen, and 25
been previously
women received
enrolled in the
transdermal 17BKEEPS trial
participated in this estradiol with pulsed
micronized
Limitations:
sub-study.
Used a calculated four
progesterone.
Conclusion:
year percentage rate of
Setting: Mayo
Cortical bone is
change for one of the
Clinic, Rochester, Instruments: Highresponsive to estrogen
measurements due to
Minnesota.
resolution peripheral
the technique of data
quantitative computed therapy.
appraisal that
Johns Hopkins
tomography
overestimated the
Evidence
(HRpQCT).
initial calculation.
Appraisal
Level of
Evidence:
Level I
Quality: A
Author Recommendations: More studies and investigation into the site specific effects of
hormone therapy on bone and dose-dependent response trials are needed. Optimal estrogen dose
therapy based on individualized risk assessment is required.
Implications: Estrogen therapy can maintain cortical bone which can prevent fractures.
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Source: Fishman, J. R., Flatt, M. A., & Settersten, R. A. (2015). Bioidentical hormones,
menopausal women, and the lure of the “natural” in U.S. anti-aging medicine. Social Science
Medicine, 132, 1-21. doi: 10.1016/j.socscimed.2015.02.027.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Qualitative
Two interrelated
Strengths: Represents
investigate
reasons of the study
a view of both
clinician’s practice Method: Interview
were that the women of clinician and patient.
and views of aging
the study actually used
and medicine, also
BHRT and the
investigate patient
clinicians actually
perceptions and
prescribed BHRT. The
experience with
Instrument:
second connection was
anti-aging
Phone interviews of
the reason the women
therapies.
clinicians about aging
had started using the
and medicine. Phone
BHRT, which was
interviews of patients
frustration with
Limitations: small
Sample:
regarding anti-aging
“traditional” physicians. participation size. The
32 clinicians
25 women
therapies.
women were actual
patients of the
Setting: Phone
clinicians.
Conclusion: Overall
interview
emphasis that BHRT is
Johns Hopkins
natural and safe. BHRT
helps a woman to stay
Evidence
Appraisal
young and healthy.
BHRT helps with
Level of
menopausal symptoms.
Evidence:
Level III
Quality: B

Author Recommendations: Did not want to come to a positive or negative conclusion but
rather understand why clinicians and patients are drawn to the use of BRHT
Implications: Women are drawn to BRHT and the clinicians who prescribe because they felt
like the clinicians listen to them and validated their concerns and menopausal symptoms. The
clinicians that prescribe BRHT regard themselves as good listeners and that they have the ability
to care holistically.
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Source: Formby, B. & Schmidt, F. (2011). Efficacy of biorhythmic transdermal combined
hormone treatment in relieving climacteric symptoms: A pilot study. International Journal of
General Medicine, 4, 159- 163. doi: 10.2147/IJGM.S16139
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Quasi-Experimental,
After three and six
Strengths:
To evaluate if a
randomized with
months, saliva levels of Randomization. All
cyclic dose of
intervention, no
estrogen and
subjects completed the
hormone treatment control.
progesterone
study. Correlations are
can relieve
significantly increased
shown by increase in
Method: Saliva and
climacteric
along with a significant serum and saliva levels
symptoms of
serum values prior to
fall in Kupperman
of hormones and
treatment, at three, six index.
menopausal
positive effects on
women.
months, and at
climacteric symptoms.
different times before
and after cream
Sample:
29 healthy, nonapplication.
Menopausal symptom
hysterectomized
Conclusion:
Limitations: No
women (age 44 –
were evaluated with a
Bioidentical hormone
control or placebo.
56 years, mean 51 questionnaire prior to
therapy at cyclical
Sampling was done
treatment, at three, and cycles, that mimic the
years).
using the most
six months.
secretory 28-day pattern convenient solution
Setting:
which is saliva and
of a healthy,
Santa Barbara,
then compared to
menstruating woman,
California, USA.
Instruments: Highserum concentrations.
demonstrates positive
performance liquid
results of both
Johns Hopkins
chromatography
physiological and
Evidence
(HPLC). Kupperman
clinical outcomes. It
Appraisal
index.
was demonstrated that
hormone therapy has a
Level of
positive effect on
Evidence:
climacteric symptoms
Level II
of menopausal women.
Quality: B
Author Recommendations: Larger studies over long-term are needed to determine long
standing effects of bioidentical hormone therapy.
Implications: Sleep difficulties and depressive symptoms are often seen in menopausal women.
Estrogen has been shown to control circadian rhythms and improve sleep and depressive
symptoms.
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Source: Gleason, C. E., Dowling, N. M., Wharton, W., Manson, J. E., Miller, V. M., Atwood, C.
S.,… & Asthana, S. (2015). Effects of hormone therapy on cognition and mood in recently
postmenopausal women: Findings from the randomized controlled KEEPS-cognitive and
affective study. PLOS Medicine, 12(6), 1-25. doi: 10.1371/journal.pmed.1001833
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Randomized Control
o-CEE group had
Strengths:
To identify if there Trial, in conjunction
clinically significant
Randomization into
are cognitive and
with parent KEEPS
change at month 48 on
groups and control
mood effects
trial.
POMS depression and
group. Consistent
related to use of
anxiety.
results. Consistent
Method: Participants
Placebo and t-E2
menopausal
recommendations.
groups showed no
hormone therapy
were randomized into
Good references and
(MHT).
three groups; oral
improvements.
comparisons to other
Global cognitive
conjugated equine
large studies. Length
performance did not
estrogens (o-CEE),
of study was four
differ between groups.
transdermal estradiol
Sample:
years.
693 women in late (t-E2), or placebo.
menopausal
Limitations: The
transition and
Instruments:
results cannot be
Cognitive and mood
Conclusion:
early
inferred past four years
Menopausal hormone
assessment data
postmenopausal
of treatment. It has
therapy does not
periods.
collected at baseline,
been shown that longer
use of HT can increase
months 18, 36, and 48. improve cognition.
Setting:
Cognitive assessment
Oral hormone therapy
risk of adverse effects.
University of
included global
does improve anxiety
Generalized due to the
Wisconsinpopulation of study,
cognitive measure and and depression,
Madison.
transdermal does not
not a representation of
four domain scores.
show benefits.
general
This test was selected
Johns Hopkins
postmenopausal US
because it was used in
Evidence
population. None of
another large study the
Appraisal
the women in study
WHIMS. Mood was
had a hysterectomy.
assessed using The
Level of
Not long enough of a
Profile of Mood States
Evidence:
trial to assess
(POMS) a survey to
Level I
dementia.
rate 65 adjectives on a
Quality: A
five-point Likert scale.
Author Recommendations: Use this data to inform women who are considering menopausal
hormone therapy. More studies and investigation is needed into the variations in dose, hormone
formulation, and route of administration specifically examining the safety of use.
Implications: With the help of their provider and with current evidence, women can make an
informed decision as to whether or not they would benefit from menopausal hormone therapy.
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Source: Iftikhar, S., Shuster, L. T., Johnson, R. E., Jenkins, S., & Wahner-Roedler, D. L. (2011).
Use of bioidentical compounded hormones for menopausal concerns: Cross-sectional survey in
an academic menopause center. Journal of Women’s Health, 20(4), 559–564. doi:
10.1089/jwh.2009.1915
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Nonexperimental;
20% of the women
Strengths: sample
assess the
survey research
surveyed used BCH and size, with an 88%
popularity of
nearly 50% of the
responds rate.
BCH, to
women surveyed were
understand beliefs, Method: Convenience familiar with BCH. No
practices, and self- Sample of 208
clear differences were
described clinical
consecutive
reported between BCH
outcomes.
participants surveyed
and CHT use on
about bioidentical
menopausal symptoms.
compounded hormone BCH users tended to
Sample: 184
knowledge.
respond positive about
consecutive
memory and fatigue
women seeking
concerns. 67% of
consultation for
Instrument: 19 Item
surveyed thought BCH
menopause.
survey; self-report.
was safer than CHT.
Limitations:
Setting: Mayo
Circumstantial and
Clinic, Women’s
Conclusion:
exploratory. Survey
Health Clinic in
The rate of use was
was not validated in
advance of the study.
Rochester,
greater than expected.
Short duration of one
Minnesota.
Because of the media
reports and notions that year.
Johns Hopkins
BCH is natural there is
Evidence
a tendency to believe it
Appraisal
is safer than CHT.
Level of
Evidence:
Level III

BCH = Bioidentical
Compounded Hormone
Therapy.
CHT = Conventional
Quality: B
Hormone Therapy.
Author Recommendations: Further studies are needed, it is important to advance our
understanding as to why women seek this treatment and what their experiences have been.
Implications: Wide variety of U.S. Food and Drug Administration approved and non-approved
hormones with differing class effects, molecular structure, origin, potency, specificity,
bioavailability, and routes of administration. There is a lack of evidence about each product
especially non-approved compounded preparations.
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Source: Kocoska-Maras, L., Radestad, A. F., Carlstrom, K., Backstrom, T., Schoultz, B. O., &
Hirschberg, A. L. (2013). Cognitive function in association with sex hormones in
postmenopausal women. Gynecological Endocrinology, 29(1), 59–62. doi:
10.3109/09513590.2012.705385
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Randomized Control
Negative associations
Strengths: Large
To investigate if
Trial
found in fluency, spatial number of participants
there is a
Method: Participants
and verbal ability in all in study.
were randomly
relationship
treatment groups except
between cognitive assigned to estrogen,
the placebo group
testosterone or placebo which found a positive
function and
serum levels of
treatment for 1 month. correlation with verbal
sex hormones.
Cognitive tests were
fluency.
performed at the end of
Sample: 200
the treatment time.
Blood samples were
naturally
postmenopausal
drawn before
beginning hormone
Limitations:
women between
Women in the estrogen
50 – 65 years old. therapy and at the end
treated group were
of treatment.
slightly older than
Cognitive test was
Setting:
women in the other
Stockholm,
measured by a mental
Sweden
rotation test. Verbal
Conclusion: Hormone
two groups. No
fluency was tested by
support for cognitive
therapy does not
test validity. Short
amount of words
Johns Hopkins
increase fluency,
Evidence
written in a 1 minute
spatial, or verbal ability. term trial.
Appraisal
time frame. Verbal
memory was tested by
using free recall.
Level of
Evidence:
Instruments:
Level: I
Correlations between
hormone levels and
Quality: B
cognition were
assessed using the
Spearman rank
correlation test. Serum
analyses were
completed using
commercial kits from
Siemens Medical
Solutions.
Author Recommendations: Study results support the hypothesis of the importance in a balance
between estrogen and testosterone for attaining optimal spatial and verbal abilities.
Implications: There are several estrogen receptors within the brain.
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Source: Nii, S., Shinohara, K., Matsushita, H., Noguchi, Y., Watanabe, K., & Wakatski, A.
(2015). Hepatic effects of estrogen on plasma distribution of small dense low-density lipoprotein
and free radical production in postmenopausal women. Journal of Atherosclerosis and
Thrombosis, 23(7), 810-818.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Randomized
In all groups it was
Strengths:
To investigate the Controlled Trial
comparatively found
Randomized to
hepatic effects of
that climacteric
treatment.
For three months 15
three different
symptoms improved for
types and different subjects received oral
all groups. CEE –
routes of estrogen estrodiol 0.625 mg per significantly reduced
administration on
day,
total cholesterol and
levels of
15 subjects received
LDL, and significantly
transdermal 50 mcg
cholesterol
increased HDL and
production.
estrodiol per day, and
triglycerides levels.
15 subjects received
Oral estrodiol–
Sample:
oral 1 mg estrodiol per significant increase in
day.
HDL Transdermal
45 healthy
Limitations:
estrodiol – significantly Small study size. Short
Japanese
decreased the
Instruments: Vital
postmenopausal
duration of study time.
triglyceride level
signs and blood
women
Setting:
samples were measured
Department of
at the start of the study Conclusion:
and then after the 3
Obstetrics and
Different hepatic effects
months of hormone
Gynecology,
can be seen with
Aichi, Medical
treatment. Blood
different routes and
University
samples consisted of
doses of estrogen.
serum triglycerides,
These different effects
LDL, total cholesterol, may be associated with
Johns Hopkins
Evidence
and HDL.
the risk of
Appraisal
cardiovascular disease
Level of
because of the
Evidence:
distribution effect of
Level I
LDL and the free
Quality: B
radical production.
Author Recommendations: Further studies are needed to demonstrate Oral versus transdermal
effects.
Implications: When the liver is stimulated it produces more triglycerides which can lead to an
increased risk of CVD.
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Source: Pingel, J., Langber, H., Skovgard, D., Koskinen, S., Flyvbjerg, A., Frystyk, J.,… &
Hansen, M. (2012). Effects of trandermal estrogen on collagen turnover at rest and in response to
exercise in postmenopausal women. Journal of Applied Physiology, 113(7).
doi:10.1152/jappiphysiol.01463.2011.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Randomized
Serum estrogen
Strengths:
assess if there is an Controlled, Crossover
increased significantly
Randomization and
effect on collagen Trial
in hormone group.
control group.
and skeletal
Significant effect
Method: Randomized between time and
muscle when
to start estrogen
exposed to
treatment observed, at
hormone therapy
hormone therapy
day five serum collagen
while exercising
transdermal patches
markers were
along with prescribed
and resting. Also,
significantly higher.
exercise and rest.
to assess if
Plasma collagen marker
Blood, urine, and
transdermal
also had a significant
dialysate examined at
hormone therapy
increase over time.
day two, three, and
effects the levels
Post-exercise insulin
five. Different
of insulin like
like growth factor
exercises were
growth factors.
increased as compared
Limitations:
Sample: Eleven, y prescribed.
to pre-exercise level.
Small number of
postmenopausal
participants. Short
women aged 60
Instruments: Blood
time frame for study.
years or older.
Serum, urine and
Missing samples
dialysate samples
Setting: Institute
during testing periods.
of Sport Medicine, examined for levels of
hormone, collagen, and Conclusion:
Bispebjerg
growth factor.
Hospital,
A combination of
Copenhagen,
exercise and short term
Denmark.
hormone replacement
Johns Hopkins
therapy increase
Evidence
collagen production.
Appraisal
Level of
Evidence: Level I
Quality: C
Author Recommendations: More studies needed with more time points to detect further
collagen changes. Placement of the hormone patch is important to receive the best effects of the
therapy.
Implications: It has been shown that muscle and bone mass are reduced as a woman ages.
Collagen is part of the structural protein in tendons and ligaments. Estrogen can be used to
stimulate collagen production which may help with muscle recovery after strenuous exercise,
and with bone collagen synthesis.
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Source: Pinkerton, J. V., & Santoro, N. (2015). Compounded bioidentical hormone therapy:
Identifying use trends and knowledge gaps among US women. Menopause, 22(9), 926-936. doi:
10.1097/GME.0000000000000420
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Nonexperimental;
Harris: two percent had Strengths:
To assess the
survey research
used compound
Number of
knowledge of the
hormone therapy. 14% participants.
difference between Method: Two different had correct knowledge
Consistent results.
compounded
about compound
surveys were
hormone therapy
completed through the hormone therapy. 76%
versus Food and
were unsure of the
internet.
Drug
Harris: Surveyed
correct answer.
Administration
women aged 45 – 60
(FDA) approved
years old who were
hormone therapy,
currently or previously Rose: twenty-one
to measure the use experiencing
percent reported current
of these therapies, menopause symptoms. or prior use. 27% did
and also to acquire
not know if their
information on
Rose: Surveyed women hormone therapy was
menopausal
compounded or
Limitations:
aged 40 years or older
experience.
personalized for them.
Estimations and
who currently or prior
Sample:
generalizations of the
use hormone therapy.
Harris Survey: 801
population on current
women
use of compounded
Rose Survey: 2044
hormone therapy – not
Setting: Internet,
a true number. No
web based, United
randomization.
States.
Johns Hopkins
Evidence
Appraisal
Conclusion:
Level of
Compounded hormone
Evidence:
therapy use is higher in
Level III
younger age groups.
Quality: A
Author Recommendations: Women considering hormone therapy should seek advice from
their physician. Physicians can educate on evidence that support the efficacy, safety, and quality
of compounded hormone therapy or Food and Drug approved hormone therapy.
Implications: Estimated that 1 – 2.5 million US women take compounded hormone therapy but
not all understand or are aware of the difference between FDA approved or compounded
hormone therapy. There can be a difference in quality among the variations of compounded
hormone therapy and safety is a concern.
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Source: Połac, I., Borowiecka, M., Wilamowska, A., & Nowak, P. (2013). Coagulation and
fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal
and oral administration. Gynecological Endocrinology, 29(2), 165–168.
doi: 10.3109/09513590.2012.730567
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Quasi Experimental
After six months the
Strengths:
assess the effects
level of Fg was higher
Intervention and
of oral versus
in the HT group.
control groups.
transdermal
Method: Blood
Transdermal route of
hormone therapy
samples were collected HT had less of an effect
on coagulation and analyzed for total clot
on hemostatic levels
fibrinolitic
formation and
overall. No significant
parameters.
fibrinolysis which
difference in Plt, APTT,
included; platelet
and triglycerides among
count, activated partial all three groups.
Sample: 54
postmenopausal
thromboplastin time,
Thrombin activity was
women
and thrombin inhibitor statistically higher in
Setting:
of fibrinolysis.
HT group.
Department of
Gynecology and
Menopausal
Instruments: Serum
Limitations: Lacks
Disorders, Polish
blood tests.
random assignment to
Mother’s
groups. Small study
Memorial
group participation.
Hospital—
Research Institute
in Lodz, Poland
Johns Hopkins
Conclusion:
Evidence
There is a difference in
Appraisal
effect of hormone
Level of
therapy on clotting
Evidence:
factors between oral
Level II
and transdermal
Quality: B
products.
Author Recommendations: The goal of hormone therapy selection for climacteric complaints
should be to choose the safest product with the lowest known changes in coagulation and
fibrinolysis markers. More studies are needed to look at efficacy and safety.
Implications: As women age the risk of cardiac disease increases. Hormone therapy has been
shown to increase arterial and venous thrombosis which can add to the risk of cardiovascular
disease in older women.
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Source: Ran, S. Y., Yu, Q., Chen, Y., & Lin, S. Q. (2017). Prevention of postmenopausal
osteoporosis in Chinese women: A 5-year, double-blind, randomized, parallel placebo-controlled
study. Climacteric, 20(4), 391-396. doi:10.1080/13697137.2017.1325469
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Randomized
Significant increase in
Strengths: Length of
assess if hormone Controlled Trial
bone mass density was
study. Controlled with
therapy is safe and Method: Estradiol
seen in hormone groups intervention. Solid
effective in
valerate and
over the first two years results.
preventing bone
but then continued to
medroxyprogesterone
loss in Chinese
acetate tablets were
decrease but remain
Women during
higher than baseline.
used for the hormone
early menopause
therapy. Starch tablets Placebo group had a
and evaluate if
were used for the
slight increase at first
there are any long placebo. All
year and then a
term effects.
participants received
significant decrease
over the five years. At
twice-daily calcium
Sample:
the end of the fifth year
and vitamin D
120 total women
bone mass density
Limitations:
supplements and
participants aged
Narrow population
remained higher than
participated in a
40 – 55 years old. standard exercise
before treatment for the group studied. Only
60 in the
hormone groups.
studied one form of
program of fast
menopausal
oral estrogen with
walking for 10 minutes
transition group
a day.
progesterone.
and 60 in the early Instrument: Dualmenopause group. energy x-ray
Setting: China
absorptiometry, bone
indexes, serum, and
urine tests at
Conclusion: Estrogen
beginning, 12, 24, 36,
Johns Hopkins
and progesterone
48 and 60 months.
Evidence
hormone therapy can
Radiographs of the
Appraisal
increase bone mineral
thoraci and lumbar
density for women in
vertebra
were
taken
at
Level of
early menopause and
beginning, 48, and 60
Evidence:
sustain bone mineral
months.
Level I
density during
Quality: A
menopausal transition.
Author Recommendations: More studies needed to evaluate effectiveness and safety of long
term effects of hormone replacement therapy for prevention of osteoporosis.
Implications: Postmenopausal women have been shown to have a loss of bone mass due to low
estrogen levels.
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Source: Ruiz, A. D. & Daniels, K. R. (2014). The effectiveness of sublingual and topical
compounded bioidentical hormone replacement therapy in post-menopausal women: An
observational cohort study. International Journal of Pharmaceutical Compounding, 18(1), 7077.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: Assess if Quasi Experimental Participants receiving
Strengths: Consistent
sublingual and
Observational Cohort
sublingual hormone
data.
topical
Study.
replacement had the
compounded
most significant
bioidentical
Method: Survey, self
reduction in symptoms.
hormone
report at start of
replacement
therapy and at three
therapy is effective and six months.
for the treatment
of vasomotor,
mood, and other
quality-of-life
symptoms for
postmenopausal
women.
Sample:
Limitations: Narrow
200 Women
Instrument: Microsoft
demographics of study
received
Corp Austin, Texas
Conclusion:
participants. Rater bias
sublingual or
is present because of
software was utilized
Oral sublingual
topical
the way the data was
to create a survey form. hormone therapy had
bioidentical
Survey was
faster and more
collected.
hormone
administered by a train significantly improved
outcomes versus topical
replacement
professional
therapy. Mean age pharmacist.
therapy. Over longer
periods of use there can
of the participants
be small improvements
was 52 years old.
in mood and night
Setting: San
sweats seen with topical
Antonio, Texas.
therapy.
Johns Hopkins
Evidence
Appraisal
Level of
Evidence:
Level II
Quality: B
Author Recommendations: More studies needed to evaluate BHRT in combination with
testosterone. More studies are needed to test compounded bioidentical hormone therapy
preparations.
Implications: This study examined pharmaceutical FDA approved bioidentical sublingual and
topical hormone medications.
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Source: Sood, R., Warndahl, R. A., Schroeder, D. R., Singh, R. J., Rhodes, D. J., WahnerRoedler, D.,… & Shuster, L. T. (2013). Bioidentical compounded hormones: A pharmacokinetic
evaluation in a randomized clinical trial. Maturitas, 74(4), 375-382.
doi: 10.1016/j.maturitas.2013.01.010
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Experimental,
The Bi-est 2.5 and 3 mg Strengths:
To compare
randomized controlled provided a lower
Randomization of
estrogen and
trial.
estrogen level as
assignment.
progesterone
compared to the
levels obtained
Vivelle-Dot patch.
after the use of
Estrogen absorption
bioidentical
with Bi-est creams
preparations and
Method: Blood
highly variable and not
samples drawn on
conventional
consistent peak of
study day one, fifteen,
hormone therapy.
absorption.
Limitations:
sixteen. Women were
Compounded
Choice of formulas
randomized to one of
Sample:
progesterone cream and was experimental due
four treatment arms.
40
capsule had comparable to lack of evidenceEstradiol-estril cream
Postmenopausal
levels in all four groups. based guidelines.
(Bi-est), placebo skin
women
Small study size.
patch, and
compounded oral
Setting:
Rochester, MN
micronized
Conclusion:
progesterone capsules. The small increases in
Estradiol-containing
Johns Hopkins
estradiol levels from the
patch (Vivelle-dot),
Evidence
Bi-est formula raises a
Appraisal
placebo cream, and
question as to whether
commercially available the reported symptom
oral micronized
Level of
relief is due to the dose
progesterone capsules
Evidence:
or a placebo effect.
Level I
(prometrium)
Quality: B
Author Recommendations: Due to the low estrogen level raises from the bioidentical
compounded formulations; there is uncertainty of a bone benefit, more studies are needed.
Implications: The term Bioidentical refers to a medication being like a human component, this
in turn leads to the belief that it is safe, and has led to an increase in popularity and use of
bioidentical hormones. Differences in serum levels may be explained by the individual
variations in skin physiology, blood flow, and hormone metabolism.
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Source: Stephenson, K., Neuenschwander, P. F., & Kurdowska, A. K. (2013). The effects of
compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune
factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in
perimenopausal and postmenopausal women. International Journal of Pharmaceutical
Compounding, 17(1) 74–85.
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Quasi-experimental
Statistically significant Strengths:
Examine the long- Study.
changes in
Randomization to
term effects of
inflammatory and
therapy.
compounded
immune signaling
bioidentical
Method: Initial
factors seen with
baseline blood samples transdermal hormone
transdermal
hormone therapy
and assessment
therapy. Statistically
on cardiovascular including vital signs, at significant decreases in
2 months, and annually Greene Climacteric
biomarkers,
hemostatic,
for 36 months.
Scale. Fasting glucose
inflammatory,
and triglycerides
immune signaling Instruments: Factor
decreased
factors; quality-of- VII, fibrinogen,
significantly.
Limitations:
life measures; and antithrombin III,
No control, no group
inflammatory and
health outcomes.
tested with placebo.
immune signaling
Sample:
factors, sex steroid
75 women in
levels. Also Green
Conclusion:
Climacteric scale,
menopausal
Study supports the use
Hamilton anxiety and
transition and
of compounded
postmenopausal
depression scale, and
transdermal
period.
Holmes Rahe stress
bioidentical hormone
scale used.
replacement therapy.
Setting:
Johns Hopkins
Evidence
Appraisal
Level of
Evidence:
Level II
Quality: B
Author Recommendations: Compounded transdermal BHRT should be considered safe and
effective therapy for menopausal symptoms.
Implications: Other studies claim that BHRT can have the same effect as medroxyprogesterone
acetate and conjugated equine estrogen, this specific study does not support this claim.

62

Source: Thompson, J. J., Ritenbaugh, C. & Nichter, M. (2017). Why women choose
compounded bioidentical hormone therapy: Lessons from a qualitative study of menopausal
decision-making. Bio Medical Central Women’s Health, 17(1). doi: 10.1186/s12905-017-0449-0
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Qualitative Study
All twenty-one women Strengths: Opinions
To Identify the
felt pushed away due
and beliefs of CBHT
reasons women
to overall frustration
past users. Highly
choose to use
Method: Semiwith traditional
educated women were
compounded
structured focus groups medicine mainly due to participants in this
bioidentical
and interviews lasting
lack of trust,
study. Several of the
hormone therapy
90 – 120 minutes.
dismissing their
participants had health
CBHT.
concerns, and seen as
related careers.
Instruments: Audio
relying on
Conclusions are well
recorded and
pharmaceuticals to
supported with other
transcribed verbatim.
treat symptoms.
evidence.
Sample/Setting:
Lack of trust in
Twenty-one
conventional HT due
women, current or
to media reports of
cancer.
previous users of
Push and Pull: 17 of
CBHT.
the 21 (81%) said they
had tried herbal
Johns Hopkins
formulas to help with
Limitations:
Evidence
menopausal symptoms Small study size, may
Appraisal
but it did not help.
not be a true
Pull: three key themes representation of the
Level of
to CBHT; it is
general population.
Evidence:
effective, it is safe, and
Level III
it is tailored to my
Quality: B
individual body.
Conclusion: Women
choose CBHT because
they consider them
safer, the clinician
listens to them and
does not discount their
symptoms or concerns.
Also, the women feel
as if they have power
and a voice when
choosing CBHT.
Author Recommendations: More studies understanding why women choose CBHT are needed.
Women would benefit from being able to voice concerns, symptoms, and preference of treatment
and also have an opportunity for a clinician to address the benefits and risks of all hormone
therapy options.
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Implications: Data has been published that indicates CBHT use has increased even though there
are FDA approved bioidentical hormone therapy products
Source: Velentzis, L. S., Banks, E., Sitas, F., Salagame, U., Tan, E. H., & Canfell, K. (2016).
Use of menopausal hormone therapy and bioidentical hormone therapy in Australian women 50
to 69 years of age: Results from a national, cross-sectional study. PLOS One, 11(3), 1-12.
doi: 10.1371/journal.pone.0146494
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Non- experimental
Current use of MHT =
Strengths:
To assess and
study. Population
13%, duration of use
Large sample size.
estimate current
based survey
<5 years was 27% and
Random selection of
use of menopause
>5 years 73% and this
participants. The use
hormone therapy
increased with age.
of the validated MHTand bioidentical
Method: Survey – self Most MHT current
related questionnaire.
hormone therapy
report.
users reported using
Data correlation with
in Australian
oestrogen only.
other studies.
women aged 50 – Instrument: Validated BHT current use was
69 years of age.
2%. Combined use of
MHT-related
BHT + MHT = 15%.
questionnaire.
Sample:
4,389 participants
returned
completed
questionnaires.
Setting: Australia
Johns Hopkins
Evidence
Appraisal

Conclusion:
Women are using more
menopausal hormone
therapy then
bioidentical hormone
therapy.

Limitations: Low rate
of completed
questionnaires – only
22%. Generalization of
the population. Selfreported data used.

Level of
Evidence:
Level III
Quality: A
Author Recommendations: Continued monitoring of the use of MHT and BHT is needed.
Implications: From past studies it has been established that MHT is effective for treatment of
menopausal symptoms but is recommended for use at the shortest duration and should not be
used for prevention of chronic diseases. BHT is not subject to the same regulatory controls as
MHT.
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Source: Whedon, J. M., KizhakkeVeettil, A., Rugo, N. A., & Kieffer, K. A. (2017). Bioidentical
estrogen for menopausal depressive symptoms: A systematic review and meta-analysis. Journal
of Women’s Health, 26(1), 18–28. doi: 10.1089/jwh.2015.5628
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Systematic review of
Within the 10 included Strengths:
Assess the
RCTs, with metastudies there was no
Randomization,
effectiveness and
analysis.
significant difference in interventions, and
safety of
the treatment group
control. Large amount
bioidentical
versus the placebo
of study subjects.
estrogens for
Randomized controlled group for change in
treatment of
trials investigating
depressive symptoms.
depression in peri menopausal women
and
who sought HT for
Secondary outcomes:
postmenopausal
treatment of reported
five of the studies
women.
depressive symptoms.
reported a significant
decrease in vasomotor
Sample/Setting:
Literature search from symptoms for the
10 included
databases: CINAHL,
Limitations:
treatment group using
studies with 1208
PubMed, Medline, and estradiol.
subjects
the Cochrane Library.
Most of the included
studies were of short
Adverse events: three
duration. All studies
studies reported
included investigated
increased vaginal
Johns Hopkins
only one form of HT;
bleeding in the
Evidence
bioidentical estradiol.
treatment group that
Appraisal
were using bioidentical
estrogens.
Level of
Evidence:
Conclusion:
Level I
Quality: A
There is no significant
evidence to support the
use of bioidentical
estradiol for
menopausal depressive
symptoms.
Author Recommendations: More studies are needed that assess different types and
combinations of bioidentical HT and nonbioidentical HT for the effectiveness of menopausal
depressive symptoms.
Implications: A better understanding of risks and benefits of bioidentical HT would help women
to be able to make a more educated decision when choosing HT.
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